TEMENOS
23.7.2020 15:02:46 CEST | Business Wire | Press release
Temenos (SIX: TEMN), the banking software company, today announced that Orange Bank Africa has gone live with cloud-native Temenos Transact delivered as SaaS. Temenos Transact core banking technology scales to support the bank to launch and drive financial inclusion in the African WAEMU region, starting with the Ivory Coast. Temenos’ cloud technology enables sustainable, long-term growth for Orange Bank Africa by reducing IT costs, operational complexity and delivering an improved cost/income ratio.
Temenos and its partner, MCB Consulting, worked closely with Orange Bank Africa to implement the solution remotely after the onset of the Covid-19 pandemic. Temenos’ core banking technology is hosted on Microsoft Azure. Temenos’ SaaS technology and dedicated team support resulted in a seamless implementation within the original project timescales despite the global emergency. Temenos’ Model Bank approach provided highly localized, pre-configured banking functionality so the new software could be deployed quickly, without the need for customization.
Banking services penetration in West Africa is relatively low compared to mobile phone penetration, leaving significant room for expansion of mobile financial services. According to recent research from the Economist Intelligence Unit , the affordability of smartphones is driving the development of mobile-only and mobile-first initiatives, like Orange Bank Africa – this was cited as the top innovation strategy by 37% of MEA-based bank executives.
Orange Bank Africa’s mobile-first banking strategy was developed to deliver financial services to consumers’ phones. Temenos’ technology will allow Orange Bank Africa to continuously innovate and provide customers with much-needed access to savings accounts and micro-loans. The new technology drives process automation for these services in order to deliver vital funding to more people at a faster rate and promote financial inclusion.
Patrick Roussel, Vice President, MEA Mobile Financial Services at Orange, commented: “Our mission is to deliver banking services to those that don’t yet have access with an offer that differentiates us from the competition: simple, accessible and above all mobile-first banking. In order for us to achieve this goal in West Africa, we needed a strategic technology partner with rich experience deploying banking software in the cloud. Temenos’ cutting-edge cloud technology, relentless focus on innovation and unrivalled regional experience makes it the perfect partner for Orange Bank Africa as we launch our operations. Temenos Transact gives us the scalability we need to grow and provide vital financial services to millions of customers.”
Jean-Michel Hilsenkopf, Chief Operating Officer, Temenos, said: “Across the globe, banks are moving to the cloud and achieving operational excellence that drives a higher banking performance. For Orange Bank Africa, the cloud is key for rapid market expansion and sustainable business growth. There is a growing need to provide people in West Africa with access to banking services and Orange Bank Africa will play a vital role in addressing this. Telcos like Orange are particularly well placed to offer differentiated banking services and enhanced customer experiences because of their established client base and mobile-centric capabilities. Temenos’ SaaS technology provides a powerful and flexible solution that will support Orange Bank Africa to continuously adapt to changes in the market and innovate quickly as customer demands evolve. We are excited to support the bank in delivering personalized mobile-banking services as they advance financial inclusion in West Africa.”
– Ends –
About Orange Bank Africa
Orange Bank Africa is a digital bank, the result of a partnership between two international groups, Orange and NSIA, both present in Africa for many years. Orange Bank Africa’s ambition is to provide as many people as possible with a micro-credit and savings solutions, directly from their mobile phone, and in complete security.
Orange Bank Africa is based in Abidjan, Ivory Coast, and is set to expand to Burkina Faso, Mali and Senegal.
About Temenos
Temenos AG (SIX: TEMN) is the world’s leader in banking software. Over 3,000 banks across the globe, including 41 of the top 50 banks, rely on Temenos to process both the daily transactions and client interactions of more than 500 million banking customers. Temenos offers cloud-native, cloud-agnostic and AI-driven front office, core banking, payments and fund administration software enabling banks to deliver frictionless, omnichannel customer experiences and gain operational excellence.
Temenos software is proven to enable its top-performing clients to achieve cost-income ratios of 26.8% half the industry average and returns on equity of 29%, three times the industry average. These clients also invest 51% of their IT budget on growth and innovation versus maintenance, which is double the industry average, proving the banks’ IT investment is adding tangible value to their business.
For more information, please visit www.temenos.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200723005528/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom